Gain Therapeutics

Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain's lead drug candidate GT-02287 for the treatment of Parkinson's disease and other neurodegenerative diseases is currently being evaluated in a Phase 1 clinical trial. With its Magellan drug discovery platform, Gain is transforming drug discovery by integrating Al, physics-based methods and supercomputing power to discover novel allosteric binding sites and potential first-in-class drug candidates from on-demand libraries with 50 billion compounds in less than 3 months.

Gain Therapeutics - Crunchbase Company Profile & Funding

Gain Therapeutics on X: #Leadership Spotlight: Dr. Terenzio

Broad Application of Gain Therapeutics' Structurally Targeted

Gain Raises $40 Million in IPO, Funds Will Advance Rare Disease

A global Swiss success story: Gain Therapeutics - Swisscore

Is Gain Therapeutics Inc (GANX) Stock a Good Value Tuesday?

Gain Therapeutics on LinkedIn: Gain Therapeutics: Tackling Rare

Gain Therapeutics secures $10 million

Gain Therapeutics' Small Molecule Approach for CNS Diseases

Jesse (@Mnhotrodbuilder) / X

Gain Therapeutics Company Profile: Stock Performance & Earnings

Roshan Ahmed - Director, Business Development at Gain Therapeutics

Gain Therapeutics cleared to start study of GT-02287 in Australia

Gain Therapeutics

The Future Is Now: Matthias Alder Of Gain Therapeutics On How